Versant Venture Capital
SelectiveFiled to raiseSan Francisco, CABiotechnology, Healthcare, PharmaceuticalsLast fund filed October 2022
6 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Versant Voyageurs III | October 2022 | $300M | $300M | 82 |
| Versant Venture Capital IX | October 2022 | $600M | $600M | 82 |
| Versant Vantage III | October 2022 | $299M | $299M | 82 |
| Versant Vantage II | November 2020 | $254M | $254M | 52 |
| Versant Voyageurs II | November 2020 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
16 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Kirk NielsenNot on the current fund | Selective | Medical devices, Biotech & pharma, Digital health | 18 |
Classified sectors of Versant Venture Capital’s own portfolio companies, based on 100 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Versant Affiliates | 44 | AcuFocus, ADVANCED ICU CARE, Alexza Pharmaceuticals, Allegro Ophthalmics, Alphaeon, ALTERG, Atreca, CareConnectMD, Cell Design Labs, Ceribell, CERO THERAPEUTICS HOLDINGS, DocMatter, Edwards Lifesciences, Equinox Ophthalmic, FIDELIS SENIORCARE, FIVE PRIME THERAPEUTICS, FLUIDIGM, Immune Design, Inari Medical, Intuity Medical, KINESTRAL TECHNOLOGIES, LENSAR, MINERVA SURGICAL, NEOVISTA, Neurolens, NOVASYS MEDICAL, Okami Medical, OneFocus Vision, OPGEN, ORAMETRIX, Oyster Point Pharma, PHASERX, Prelude, REDBRICK HEALTH, Relievant MedSystems, RENNOVIA, RxSight, Sebacia, SECOND SIGHT MEDICAL PRODUCTS, Sequent Medical, Sympara Medical, TearClear, VERACYTE, ViaLase |
| U.S Venture Partners | 5 | Inari Medical, Intuity Medical, Okami Medical, Sequent Medical, ViaLase |
| $140M |
| $140M |
| 87 |
| Versant Venture Capital VIII | November 2020 | $560M | $560M | 87 |
| Versant Vantage IFiled to raise in 2019, with no closing reported yet. | 2019 | $150M | $0 | 0 |
| Versant Venture Capital VII | September 2018 | $600M | $600M | 74 |
| Versant Voyageurs I | April 2018 | $102M | $102M | 14 |
| Versant Voyageurs I Feeder | April 2018 | $20M | $20M | 1 |
| Versant Venture V AIV | November 2016 | $22M | $22M | 32 |
| Versant Venture Capital VI | November 2016 | $400M | $400M | 57 |
| Versant Venture V AIV Feeder Holdings | November 2016 | $5.3M | $5.3M | 7 |
| Versant Venture Capital V | October 2013 | $300M | $296M | 86 |
| Versant Side Fund II | October 2001 | $3.6M | $3.6M | 16 |
| VERSANT SIDE FUND I | 2000 | $5M | $5M | 18 |
| VERSANT AFFILIATES FUND I-B | 2000 | $12M | $12M | 72 |
| VERSANT AFFILIATES FUND I-A | 2000 | $5.2M | $5.2M | 37 |
| 2 |
| Alex Mayweg | Quiet | Biotech & pharma | 5 | 0 |
| Barbara LubashNot on the current fund | Quiet | Healthcare services, Digital health | 4 | 0 |
| Bradley Bolzon | Quiet | Biotech & pharma | 10 | 0 |
| Brian AtwoodNot on the current fund | Quiet | Biotech & pharma, Fintech | 8 | 0 |
| Carlo Rizzuto | Quiet | Biotech & pharma | 10 | 0 |
| Charles WardenNot on the current fund | Quiet | Medical devices, AI & machine learning, Biotech & pharma | 8 | 0 |
| Clare Ozawa | Quiet | Biotech & pharma | 8 | 0 |
| Donald MilderNot on the current fund | Quiet | Medical devices | 3 | 0 |
| Jerel Davis | Quiet | Biotech & pharma | 13 | 0 |
| Rebecca RobertsonNot on the current fund | Quiet | Medical devices, Digital health, Robotics & hardware | 5 | 0 |
| Robin PraegerNot on the current fund | Quiet | None listed | 0 | 0 |
| Ross JaffeNot on the current fund | Quiet | Medical devices, Digital health | 5 | 0 |
| Samuel ColellaNot on the current fund | Quiet | Biotech & pharma, Climate & energy, Manufacturing & industrials | 5 | 0 |
| Thomas Woiwode | Quiet | Biotech & pharma | 13 | 0 |
| William LinkNot on the current fund | Quiet | Medical devices, Biotech & pharma, Digital health | 16 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Versant Venture Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 4 |
| Cotera, Sequent Medical, TWELVE, ZYGA TECHNOLOGY |
| Arboretum Ventures | 3 | ADVANCED ICU CARE, FIDELIS SENIORCARE, ViaLase |
| Lightstone Singapore | 3 | GLUMETRICS, HOLAIRA, TWELVE |
| Lightstone Ventures | 3 | GLUMETRICS, HOLAIRA, TWELVE |
| Stack Infrastructure | 3 | Inari Medical, Okami Medical, Sequent Medical |
| Vivo Innovation | 3 | Aligos Therapeutics, Kanyos Bio, MINERVA SURGICAL |
| Westlake Biopartners | 3 | Cell Design Labs, Ceterix Orthopaedics, REDBRICK HEALTH |
| Aditum Bio | 2 | Century Therapeutics, Graphite Bio |
| ARCH Venture Partners | 2 | PHASERX, Vividion Therapeutics |
| Highland Capital Partners | 2 | FIDELIS SENIORCARE, OPGEN |
| MPM BioVentures | 2 | Aligos Therapeutics, Firefly Bio |
| Polaris Partners | 2 | Jnana Therapeutics, Quentis Therapeutics |
| Samsara Biocapital | 2 | Chinook Therapeutics U.S., Tentarix Biotherapeutics |
A shared board seat: a company where filings name a Versant Venture Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.